Introduction {#Sec1}
============

Since its discovery in *Drosophila Melanogaster*^[@CR1]^, Hippo pathway has gained ever-increasing attention. Nowadays, the involvement of Hippo pathway in cancer development and progression is well recognised. However, the different and sometimes controversial roles that it may play rise the scientific interest about this pathway. The main example is the enhanced immune response against the tumor after depletion of the LATS1-2 oncosuppressors observed in immune-competent mice^[@CR2]^. Nevertheless, the canonical oncosuppressor role is the widely accepted one^[@CR3],[@CR4]^. In this view, the kinases axis, represented by STK3-4/LATS1-2, works as a brake, controlling cell cycle, apoptosis and cell patterning, thus avoiding uncontrolled proliferation and loss of epithelial-like features. LATS kinases can be activated by a great variety of stimuli through different groups of kinases, such as MAP4Ks and TAOKs^[@CR3]^. The activity of these kinases depends on the presence of co-activators, among which SAV1, NF2 and FRMD6 represents the first to be discovered^[@CR1],[@CR5]^.

The final outcome of Hippo pathway is the LATS-mediated phosphorylation of YAP1, mainly at the residue S127, leading to its cytoplasmic retention and eventually degradation^[@CR6]^. Unphosphorylated YAP1, together with WWTR1, activates the TEAD1-4-mediated transcription in the nucleus, representing the cancer progression accelerator. Finally, VGLL4 is a peptide acting as an oncosuppressor by competing with YAP1-WWTR1 complex to TEADs binding^[@CR3]^ (Fig. [1](#Fig1){ref-type="fig"}). The presence of natural YAP1 competitor uncovered a new scenario to counterbalance the insufficient Hippo pathway oncosuppressor activity. Several molecules are capable to interfere with YAP1 activity by both mimicking VGLL4 function and preventing YAP1-WWTR1 interaction^[@CR7]^. Among YAP1 inhibitors, the photosensitizer verteporfin, already approved by the Food and Drug Administration for the macular degeneration treatment, showed excellent results both *in vitro* and in mice, with no or limited side effects^[@CR8],[@CR9]^. Verteporfin is then one of the main candidate to move a step forward as a therapeutic agent for YAP1 inhibition. In the present study, we conducted a data analysis of all solid tumor datasets of The Cancer Genome Atlas (TCGA) except pure sarcomas, and a review of literature to investigate the impact of the Hippo pathway dysregulation on survival of cancer patients, providing food for thought and data-driven proposals for approaching future Hippo-directed therapies.Figure 1Hippo pathway. In orange are kinases, in green coactivators or scaffold proteins and in yellow transcription factors or proteins interacting with transcription factors. Green lines refer to active Hippo pathway, which leads to YAP1-WWTR1 inactivation; red lines relate the TEAD-mediated transcription, when the pathway is inactive.

Results {#Sec2}
=======

Power analysis and definitive datasets {#Sec3}
--------------------------------------

Thirteen of the twenty-nine downloaded TCGA datasets had β above 0.8 with the set parameters and were selected for further analyses. Details and covariates for each dataset were reported in Table [1](#Tab1){ref-type="table"}.Table 1Results of power analysis.DatasetTCGA idSample sizeProbability of the eventβ (RR = 2.3)Covariates**Ovarian Serous Cystadenocarcinoma**OV2900.56550.9990grade, age, clinical stage**Kidney Renal Clear Cell Carcinoma**KIRC5200.30580.9987pathologic tumor stage**Head and Neck Squamous Cell Carcinoma**HNSC4770.33330.9987tobacco smoking indicator, age, clinical stage**Lung Squamous Cell Carcinoma**LUSC4690.32200.9980pathologic stage, age**Skin Cutaneous Melanoma**SKCM3930.33590.9948pathologic tumor stage**Lung Adenocarcinoma**LUAD4680.25430.9903pathologic tumor stage, age**Bladder Urothelial Carcinoma**BLCA3890.27510.9826pathologic tumor stage, age, grade**Glioblastoma**GBM1560.67950.9820age**Brain Lower Grade Glioma**LGG5050.18220.9653age, grade**Liver Hepatocellular Carcinoma**LIHC2850.23510.8962pathologic tumor stage, grade, vascular invasion**Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma**CESC2790.21510.8616clinical stage**Mesothelioma**MESO840.66670.8384pathologic stage**Pancreatic Adenocarcinoma**PAAD1570.35030.8300pathologic tumor stage, residual tumorEsophageal CarcinomaESCA1370.32850.7502Colorectal AdenocarcinomaCOADRED3230.13310.7323Uterine CarcinosarcomaUCS550.56360.5860Breast Invasive CarcinomaBRCA7590.03950.5777Kidney Renal Papilllary Cell CarcinomaKIRP2390.11300.5334Adrenocortical CarcinomaACC720.30560.4554CholangiocarcinomaCHOL340.44120.3321Uterine Corpus Endometrial CarcinomaUCEC1720.07560.2948Uveal MelanomaUVM790.16460.2923Thyroid CarcinomaTHCA4350.02530.2565Prostate AdenocarcinomaPRAD4960.01610.1986Kidney ChromophobeKICH630.11110.1777Pheochromocytoma and ParagangliomaPCPG1780.03370.1598ThymomaTHYM1170.05130.1591Stomach AdenocarcinomaSTAD150.33330.1349Testicular Germ Cell CancerTGCT1310.01530.0802In bold are datasets with β above 0.8 that were selected for further analyses. For these datasets, clinical-pathological covariates affecting patients' survival according to the eighth edition of the American Joint Committee on Cancer are listed. RR, postulated risk ratio.

Survival analyses {#Sec4}
-----------------

Univariate and multivariate results were summarized in Table [2](#Tab2){ref-type="table"}, p values of univariate and multivariate analyses were reported in Supplementary Tables [S1](#MOESM1){ref-type="media"} and [S2](#MOESM1){ref-type="media"} respectively. Briefly, univariate analyses showed that 12 out of 13 cancer models had at least one Hippo gene associated with patients prognosis and ten datasets had 3 or more significant genes. Brain lower grade glioma and kidney renal clear cell carcinoma had the higher number of Hippo genes associated with patients' survival, 16 and 15 respectively, whereas liver hepatocellular carcinoma was the only dataset with no significant genes. With regard to genes, *TEAD4* and *LATS2* were the most frequently associated with patients' survival, in 6 and 5 out of 13 datasets respectively. Genes and clinical-pathological parameters resulting associated with prognosis after univariate analyses were then used in the multivariate cox regression. Again, 12 out of 13 datasets had at least one Hippo gene as independent survival predictor, and *TEAD4* resulted an independent prognostic factor in 3 different datasets. Survival curves of the independent predictors are reported in Fig. [2](#Fig2){ref-type="fig"} and in Supplementary Figure [S1](#MOESM1){ref-type="media"}.Table 2Results of univariate and multivariate analyses.DatasetPrognostic factorIndependent prognostic factorHazard ratio (95% CI)DatasetPrognostic factorIndependent prognostic factorHazard ratio (95% CI)OV*MAP4K2*yes0.71 (0.52--0.97)LGG*LATS2*noage (58 years)no*MAP4K1*noKIRC*FRMD6*no*MOB1A*no*LATS1*no*MOB1B*no*LATS2*no*NF2*no*MAP4K1*no*RASSF1*no*PTPN14*no*STK3*no*RASSF1*no*STK38*no*RASSF6*no*STK4*no*SAV1*no*TAOK2*no*TAOK1*no*TEAD2*yes0.55 (0.31--0.98)*TAOK3*yes1.66 (1.13--2.45)*TEAD3*no*TEAD1*no*TEAD4*no*TEAD3*yes0.69 (0.47--0.99)*VGLL4*no*TEAD4*no*WWTR1*no*TNIK*no*YAP1*no*WWTR1*yes1.78 (1.09--2.89)age (41 years)yes5.16 (3.00--8.90)pathologic tumor stageyesstage III: 2.40 (1.52--3.78); stage IV: 6.81 (4.41--10.51)gradeyesG3: 2.54 (1.47--4.41)HNSC*MAP4K1*noCESC*LATS1*no*RASSF1*yes1.61 (1.13--2.31)*LATS2*yes0.40 (0.23--0.72)*TAOK2*no*MAP4K1*yes1.80 (1.05--3.08)*WWTR1*no*TNIK*noLUSC*LATS2*noclinical stageyesstage IV: 2.43 (1.18--5.02)*MAP4K2*yes0.63 (0.45--0.88)*MAP4K5*noMESO*FRMD6*no*MINK1*yes0.70 (0.50--0.97)*MAP4K4*yes0.45 (0.23--0.88)*WWC1*no*RASSF6*noSKCM*PTPN14*yes0.66 (0.46--0.95)*SAV1*yes2.42 (1.28--4.58)*TAOK3*no*STK38L*no*TEAD4*yes0.69 (0.48--0.97)*TAOK3*nopathologic tumor stageno*TNIK*noLUAD*FRMD6*yes0.66 (0.45--0.96)PAAD*VGLL4*no*LATS2*no*FRMD6*no*TEAD4*no*MAP4K4*nopathologic tumor stageyesstage II: 2.40 (1.50--3.83); stage III: 3.83 (2.39--6.14); stage IV: 3.82 (1.93--7.56)*MOB1A*noBLCA*TEAD4*yes0.66 (0.44--0.97)*NF2*noage (69 years)yes1.61 (1.09--2.37)*PTPN14*nopathologic tumor stageyesstage III: 2.10 (1.13--3.92); stage IV: 3.80 (2.11--6.86)*SAV1*noGBM*MAP4K2*no*STK3*no*RASSF1*no*TAOK2*no*TEAD2*yes1.73 (1.16--2.58)*TEAD4*yes0.40 (0.22--0.75)*TNIK*yes1.52 (1.01--2.29)*YAP1*noLIHCpathologic tumor stageyesstage IV: 5.21 (1.58--17.19)pathologic tumor stagenovascular invasionyesmicro: 0.36 (0.14--0.92); none: 0.36 (0.16--0.81)residual tumoryesR1: 3.03 (1.57--5.85)Prognostic factor and independent prognostic factor refer to univariate and multivariate results respectively. Hazard ratio and 95% CI was reported only for independent prognostic factors. CI, confidence interval.Figure 2Kaplan-Meier curves. In the panel are Kaplan-Meier curves of the four independent predictors that correlated with YAP1 protein, coherently with the canonical role of the Hippo pathway. In detail: (**a**) *TEAD3* in Kidney Renal Clear Cell Carcinoma; (**b**) *RASSF1* in Head and Neck Squamous Cell Carcinoma; (**c**) *TEAD4* in Bladder Urothelial Carcinoma; (**d**) *TEAD2* in Brain Lower Grade Glioma. The log-rank p values are also reported.

mRNA-protein correlation {#Sec5}
------------------------

Genes resulted as independent predictors were correlated with the expression of YAP1 and YAP1pS127 proteins. YAP1 and YAP1pS127 expression levels were always highly correlated, whereas a significant correlation between mRNA levels of Hippo genes and at least one of YAP1 or YAP1pS127 proteins was found in 7 datasets. Further details were reported in Table [3](#Tab3){ref-type="table"} and Supplementary Figure [S2](#MOESM1){ref-type="media"}.Table 3TCGA data analyses summary.Data setIndependent predictor (mRNA)Worse prognosis (predictor)Theoretical effect on Hippo pathwayTheoretical effect on TEAD-mediated transcriptionConcordance with role in Hippo pathwayCorrelation with YAP1 proteinOV*MAP4K2*highactivationinhibitionnonoKIRC*TAOK3*lowactivationinhibitionnoinverse*TEAD3*high/activationyesdirectWWTR1low/activationnonoHNSC*RASSF1*lowactivationinhibitionyesinverseLUSC*MAP4K2*highactivationinhibitionnono*MINK1*highactivationinhibitionnonoSKCMPTPN14highactivationinhibitionnono*TEAD4*high/activationyesnoLUAD*FRMD6*highactivationinhibitionnonoBLCA*TEAD4*high/activationyesdirectGBM*TEAD2*low/activationnodirect (only with YAPpS127)*TNIK*lowactivationinhibitionyesnoLGG*TEAD2*high/activationyesdirectLIHC/CESC*LATS2*highactivationinhibitionnodirect*MAP4K1*lowactivationinhibitionnonoMESO*MAP4K4*highactivationinhibitionnono*SAV1*lowactivationinhibitionyesnoPAAD*TEAD4*high/activationyesnoFor each dataset, independent predictors, correlation with YAP1 protein and congruence with the theoretical role within Hippo pathway are indicated.

Review of literature {#Sec6}
--------------------

Seventy-two original articles associated 17 of the 32 Hippo genes with patients' survival in more than 20 human cancers. Gastric and colorectal cancers were the most frequently tumors reporting association of Hippo genes with patients' prognosis; whereas the most represented gene was *YAP1*, reported as prognostic factor in 29 different studies in 14 cancer models. The majority of these 29 studies were conducted on a protein level and, in all but 2, patients with a high expression level of YAP1 had a lower survival rate. In addition, more than 10 studies associated only nuclear and not cytoplasm staining with patients' prognosis. Table [4](#Tab4){ref-type="table"} summarizes the review of literature, and Fig. [3](#Fig3){ref-type="fig"} sums up the overall results.Table 4Review of literature.GeneCancer modelStudymRNA/ proteinn of casesUnivariate p valueMultivariate p valueworse prognosis (low/high)Notes, score and cutoff*LATS1*gastric cancerZhang J *et al*.^[@CR17]^protein890.00130.017lowSE × I, max 12 (0--3 vs 4--12)gliomaJi T *et al*.^[@CR18]^protein103\<0.001\<0.001lowSE + I, max 7 (0--1 vs 2--3 vs 4--5 vs 6--7)non-small-cell lung cancerLin X-Y *et al*.^[@CR19]^protein1360.035NAlowSE × I, max 12 (0 vs 1--3 vs 4--12)ovarian serous carcinomaXu B *et al*.^[@CR20]^protein570.0150.006lowSE × I, max 12 (0--1 vs 4--12)*LATS2*nasopharyngeal carcinomaZhang Y *et al*.^[@CR21]^protein2200.0070.037highSE + I, max 7, median value as cutofflung adenocarcinomaLuo SY *et al*.^[@CR22]^protein490.0550.036lowSEP × I, max 300, mean value as cutoffnon-small-cell lung cancerWu A *et al*.^[@CR23]^protein730.0010.002lowsum of cytoplasm and nuclear staining score, the first is SE × I (0--9), the second is based on I (0--3), max 12 (0--6 vs 7--12)*MAP4K4*breast cancerZhang X *et al*.^[@CR24]^protein820.021NAhighSE + I, max 7 (0--2 vs 3--7)colorectal cancerHao J-M *et al*.^[@CR25]^protein1810.029NAhighSE × I, max 12 (0--3 vs 4--12)hepatocellular carcinomaLiu A-W *et al*.^[@CR26]^protein4000.0190.014highmedian SEP as cutofflung adenocarcinomaQiu M-H *et al*.^[@CR27]^protein3090.0140.009highmedian SEP as cutoffpancreatic ductal adenocarcinomaLiang JJ *et al*.^[@CR28]^protein660.0250.025highmedian SEP as cutoff*MAP4K5*pancreatic cancerWang OH *et al*.^[@CR29]^protein1050.020.012lownegative or weak staining vs moderate or strong staining*MOB1A*intrahepatic cholangiocarcinomaSugimachi K *et al*.^[@CR30]^protein880.0202n.s.lowSE × I, max 12, unspecified cutoff*NF2*hepatocellular carcinomaLuo Z L *et al*.^[@CR31]^protein1480.013NAlowSE × I, max 12, median as cutoffmesotheliomaMeerang M *et al*.^[@CR32]^protein1450.030.01lowSE × I, max 3 ( ≤ 0.5 vs \> 0.5)*RASSF1*renal clear-cell carcinomaKlacz J *et al*.^[@CR33]^mRNA860.0040.02lowqRT-PCR, RASSF1A isoform, median as cutoffesophageal squamous cell carcinomaGuo W *et al*.^[@CR34]^protein141\<0.050.04lowRASSF1A isoform,SE + I, max 6 (0--2 vs 3--6)esophageal squamous cell carcinomaZhang Y *et al*.^[@CR35]^protein76\<0.001\<0.001lowSE + I, max 6 (0--1 vs 2--6)*RASSF6*colorectal cancerZhou R *et al*.^[@CR36]^protein127\<0.0010.03lowSE × I, ROC curve to set the cutoffgastric cancerWen Y *et al*.^[@CR37]^protein264\<0.001\<0.001lowSE + I, max 6 (0--2 vs 3--4 vs 5--6)gastric cardia adenocarcinomaGuo W *et al*.^[@CR38]^protein106\<0.050.04lowSE + I, max 6 (0--2 vs 3--6)pancreatic ductal adenocarcinomaYe H-L *et al*.^[@CR39]^protein960.0210.006lowSE + I, max 6 (0--2 vs 3--6)*SAV1*pancreatic ductal adenocarcinomaWang L *et al*.^[@CR40]^protein83\<0.0010.002lowSE × I, max 9 (0--3 vs 4--9)*STK4*breast cancerLin X *et al*.^[@CR41]^protein1100.0270.03low10% of SEP as cutoffbreast cancerLin X-Y *et al*.^[@CR42]^protein980.0100.002lowdetection on plasma by ELISA, average as cutoffcolorectal cancerYu J *et al*.^[@CR43]^mRNA460.0008NAlowmicroarray, ROC curve to set the cutoffcolorectal cancerMinoo P *et al*.^[@CR44]^protein14200.014\
0.0001n.s.\
0.03lowSEP, ROC curve to set the cutoff, p values refer to mismatch-repair proficient and deficient subgroups respectivelycolorectal cancerZlobec I *et al*.^[@CR45]^protein14200.002\<0.05lowSEP, ROC curve to set the cutoff*TEAD1*hepatocellular carcinomaGe X and Gong L 2017^[@CR46]^mRNA600.002NAhighqRT-PCR, relative log2 transformation (positive vs negative log2 values)prostate cancerKnight JF 2008^[@CR47]^protein1470.0092\
0.0009n.s.\
0.037high\
highp values refer to SE (zero vs focal vs diffuse) and I (0 vs 1 vs 2 vs 3) respectively, considered as separate parameters*TEAD4*colorectal cancerLiu Y *et al*.^[@CR48]^protein4160.0002NAhighnuclear staining, positive vs negative stainingovarian cancerXia Y *et al*.^[@CR49]^protein45\<0.001NAhighSE + I, max 5 (0--1 vs 2--5)*TNIK*colorectal cancerTakahashi H *et al*.^[@CR50]^protein220\<0.0010.011highexpression of the protein at the invasive tumor front, SE + I, max 7 (0--5 vs 6--7)hepatocellular carcinomaJin J *et al*.^[@CR51]^protein3020.0010.003highphosphorylated protein, negative or weak vs moderate or strongpancreatic cancerZhang Y *et al*.^[@CR52]^protein910.021n.s.highSEP, median value as cutoff*VGLL4*gastric cancerJiao S *et al*.^[@CR53]^protein910.04160.0215lowSE × I, max 12 (0--1 vs 2--12)*WWC1*gastric cancerYoshihama Y *et al*.^[@CR54]^protein1640.037NAhighlow expression of atypical protein kinase Cλ/τ subgroup, I compared to normal tissue, score 2 is comparable to normal tissue staining, max 3 (0--1 vs 2--3)*WWTR1*colorectal cancerWang L *et al*.^[@CR55]^protein168\<0.0010.050highSE × I, max 12 (0--4 vs 5--12)esophagogastric junction adenocarcinomaSun L *et al*.^[@CR56]^protein135\<0.0010.022highSE × I, max 12 (0--4 vs 5--12)hepatocellular carcinomaGuo Y *et al*.^[@CR57]^protein180\<0.05NAhighSE × I, max 12 (0--4 vs 5--12)hepatocellular carcinomaHayashi H *et al*.^[@CR58]^mRNA110\<0.05NAhighqRT-PCR, 70th percentile as cutoffnon-small-cell lung cancerXie M *et al*.^[@CR59]^protein1810.0020.006highpositive vs negative stainingoral cancerLi Z *et al*.^[@CR60]^protein1110.00080.003highSE × I, max 12 (0--4 vs 5--12)retinoblastomaZhang Y *et al*.^[@CR61]^protein430.0480.049highunspecified cutofftongue squamous cell carcinomaWei Z *et al*.^[@CR62]^protein520.02040.008highSE × I, max 12 (0--4 vs 5--12)uterine endometrioid adenocarcinomaZhan M *et al*.^[@CR63]^protein550.018n.s.highSEP × I, max 300 (\<100 vs \>100)*YAP1*adrenocortical cancerAbduch R H *et al*.^[@CR64]^mRNA310.05NAhighpediatric patients, qRT-PCR, unspecified cutoffbladder urothelial carcinomaLiu J-Y *et al*.^[@CR65]^protein213\<0.0010.003highpositive vs negative stainingbreast cancerCao L *et al*.^[@CR66]^protein3240.005NAlownuclear staining, SEP × I, max 300, median value as cutoff, luminal A subgroupsbreast cancerKim H M *et al*.^[@CR67]^protein1220.008\
0.003NAhigh\
highmetastatic patients, nuclear staining, SE × I, max 6 (0--1 vs 2--6), p values refer to YAP e pYAP respectivelybreast cancerKim S K *et al*.^[@CR68]^protein6780.024n.s.highnuclear staining, negative or weak staining vs moderate or strong staining in more than 10% of tumor areaintrahepatic cholangiocarcinomaSugimachi K *et al*.^[@CR30]^protein880.02420.0093highnuclear staining, SE × I, max 12 (0--3 vs 4--12)cholangiocarcinomaPei T *et al*.^[@CR69]^protein900.0160.026highnegative or weak vs strong staining, the cutoff between weak and strong staining is the median value of the integrated optical densitycolorectal cancerWang Y *et al*.^[@CR70]^protein1390.00030.0207highpositive vs negative staining, positive defined as strong cytoplasmic staining in more than 50% of tumor cells or nuclear staining in more than 10% of tumor cellscolorectal cancerWang L *et al*.^[@CR55]^protein1680.0060.021highSE × I, max 12 (0--4 vs 5--12)esophageal squamous cell carcinomaYeo M-K *et al*.^[@CR71]^protein1420.0060.034highnuclear staining, SE × I, mean value as cutoffgallbladder cancerLi M *et al*.^[@CR72]^protein52\<0.010.020highnuclear staining, SE + I, max 6 (0--2 vs 3--6)gastric cancerHuang S *et al*.^[@CR73]^protein120\<0.001\<0.001highnuclear staining, SE × I, max 9 (0--3 vs 4--9)gastric cancerSun D *et al*.^[@CR74]^protein270\<0.001NAhighSE × I, max 12 (0--3 vs 4--12)gastric adenocarcinomaLi P *et al*.^[@CR75]^protein1610.0010.015highSE × I, max 12 (0--3 vs 4--12)intestinal type gastric cancerSong M *et al*.^[@CR76]^protein1170.0240.018highnuclear staining, SEP (50% as cutoff)gastric cancerKang W *et al*.^[@CR77]^protein1290.021n.s.highnuclear staining, SEP (0% vs ≤ 10% vs 10% to 50% vs \> 50%), YAP1 nuclear staining is an independent prognostic marker in stage I-II subgroupgliomaLiu M *et al*.^[@CR78]^protein720.0002\<0.001highstaining quantified by softwarecholangiocarcinomaLee K *et al*.^[@CR79]^protein880.005NAhighintrahepatic pT1 subgroup, nuclear staining, staining intensity ≥ 2 + in more than 5% of tumor cells as cutoffhepatocellular carcinoma and hepatic cholangiocarcinomaWu H *et al*.^[@CR80]^protein137\
1220.001\
0.0130.008\
0.026high\
highSE × I, max 12 (0--3 vs 4--12)hepatocellular carcinomaXu B *et al*.^[@CR81]^protein89\<0.001NAhighunspecified cutoffhepatocellular carcinomaHayashi H *et al*.^[@CR58]^mRNA110\<0.05NAhighqRT-PCR, 75th percentile as cutoffhepatocellular carcinomaHan S-X *et al*.^[@CR82]^protein390.0420.005highSE × I, max 12 (0--3 vs 4--12)lung adenocarcinomaSun P-L *et al*.^[@CR83]^protein2050.0010.013lowcytoplasmic staining, strong cytoplasmic staining in more than 50% of tumor cells as cutoffmelanomaMenzel M *et al*.^[@CR84]^protein3800.013NAhighstaining compared to that of hair bulb stem cells: 0 = no staining, 1 = weaker, 2 = comparable, 3 = stronger (0 vs 1 vs 2 vs 3)ovarian cancerHe C *et al*.^[@CR85]^protein3420.018NAhighstaining quantified by softwareovarian cancerXia Y *et al*.^[@CR49]^protein460.002NAhighSE × I, max 5 (0--1 vs 2--5)pancreatic ductal adenocarcinomaSalcedo Allende MT *et al*.^[@CR86]^protein640.0720.032highSEP × I, max 300, unspecified cutoffpancreatic ductal adenocarcinomaZhao X *et al*.^[@CR87]^protein96\<0.0010.004highSE × I, max 9 (0--4 vs 5--9)pancreatic ductal adenocarcinomaWei H *et al*.^[@CR88]^protein63\<0.05NAhighnuclear staining,SEP, 10% as cutoffIn univariate and multivariate p values columns, p are reported as indicated in the study. SE staining extend; I intensity; SEP staining extend percentage; NA not available; n.s. not significant.Figure 3Results summary. For each analysed TCGA datasets, grey circles indicate the presence of: an independent predictor among Hippo components (multivariate survival analysis); a correlation of the independent predictor with YAP1 protein; coherence between poor survival and canonical oncosuppressor role of the Hippo pathway; and the presence of at least 2 independent studies confirming our results.

Discussion {#Sec7}
==========

Genetic alterations affecting the Hippo pathway components are generally rare events in the cancer biology landscape, except for malignant pleural mesothelioma and some tumors of the nervous system, such as neurofibromas, meningiomas and shwannomas^[@CR4],[@CR10],[@CR11]^. However, the disruption of this pathway was reported in several human cancers. Epigenetic events, post-transcriptional and post-translational modifications can all play a crucial effect on this pathway^[@CR12]^, and simultaneously monitoring all these alterations is impracticable. If a positive aspect can exist in this scenario, it is the converging effect of a great variety of dysregulation on a single protein expression and/or phosphorylation, YAP1. Herein, we investigated the effect of mRNA and protein levels of the Hippo pathway components on survival of cancer patients by both analysing TCGA data and reviewing the literature.

In the large majority of analysed datasets, the mRNA levels of the Hippo pathway components were associated with patients' survival, and most importantly, in almost all cancer models taken into account at least one of the considered genes was an independent predictor (Table [2](#Tab2){ref-type="table"}). We then decided to move another step forward, on a protein level, to understand if the predictors correlated with the effector, YAP1 protein and its phosphorylation status.

The protein levels from TCGA were obtained by standard reverse phase protein lysate microarray, a technique that allows to reliably estimate protein levels and post-translational modifications, without considering the initial compartmentalization^[@CR13]^. As a consequence, we always found a very high direct correlation between YAP1 and YAP1pS127 that theoretically should determine a very different output: TEAD-mediated transcription and YAP1 inactivation respectively. Considering that this incongruence should be overcome by other techniques such as immunohistochemistry (IHC), we found that 7 of the 19 predictors were correlated with high levels of YAP1 protein (Table [3](#Tab3){ref-type="table"}). Interestingly, *MAP4Ks* never correlated with YAP1 protein, and, when they were independent predictors, very often the expression levels associated with a worse prognosis were not justified by their theoretical role within Hippo pathway. Nevertheless, this is in agreement with other well-known functions of MAP4Ks^[@CR14]^ and with 8 out of 9 previous studies that associated high MAP4Ks levels with a worse prognosis (Table [4](#Tab4){ref-type="table"}). Assuming that MAP4Ks should not play a pivotal role in the regulation of Hippo pathway, more than half (7 out of 12) of the other independent predictors were correlated with YAP1. In addition, because of mRNA levels were compared with survival of patients, some incongruence should be accounted for feedback mechanisms such as in the case of *LATS2*. In fact, *LATS2* is a direct transcriptional target of activated YAP1-WWTR1-TEADs^[@CR15]^, thus explaining high *LATS2* mRNA levels associated with poor prognosis.

Yet, more than half of Hippo genes were already associated with patients' prognosis in different independent studies in several human cancers (Table [4](#Tab4){ref-type="table"}). High expression levels of YAP1 were repeatedly reported as a poor prognostic factor, especially in gastric, colorectal, hepatocellular, pancreatic and lung cancer. These cancer types should then really benefit from treatment with YAP1 inhibitors, as well as kidney renal clear cell carcinoma, head and neck carcinoma, bladder cancer and lower grade glioma, in which we found not only at least one Hippo gene as an independent prognostic factor, but also a correlation between the predictors and YAP1 protein levels, coherently with their role within Hippo pathway.

In conclusion, the independent impact of YAP1 activation on patients' survival was repeatedly proven by several independent studies and in a large variety of human cancers. Several molecules can disrupt YAP1 activation, and showed very promising results both *in vitro* and in mice. Some of these molecules directly bind to YAP1 thus allowing to use its expression levels as a potential predictive biomarker. Moreover, YAP1 evaluation by IHC would provide not only the direct quantification of the protein levels, but also the visualization of its compartmentalization: this is a relevant point because nuclear YAP1 is the real biological effector and strongly correlated with patients prognosis. Indeed, YAP1 quantification by IHC needs to be uniformly assessed because of the wide interpretation criteria that still exist.

Finally, Kary Mullis truly said that the majority of the scientific studies are correlation and not cause-effect, but when a great number of independent studies point in the same direction, maybe the time is ripe to move a step forward.

Methods {#Sec8}
=======

Selection of genes and datasets {#Sec9}
-------------------------------

Thirty-two genes belonging to the core Hippo pathway were considered in the present study (Table [5](#Tab5){ref-type="table"}). Level 3 RNA Seq, level 3 reverse phase protein lysate microarray and clinical data of all solid tumor datasets of TCGA except pure sarcomas were downloaded from cBioPortal ([www.cbioportal.org](http://www.cbioportal.org)). In order to select datasets for further investigation, power analysis for survival data was performed with the powerSurvEpi R package version 0.0.9. In detail, two hypothetical groups with the same number of patients and the same probability of death were considered. Moreover, postulated risk ratio of 2.3 and alpha of 0.05 were set to assess the statistical power of each dataset. Datasets with β above 0.8 were selected for further analyses.Table 5List of Hippo genes considered in the study.GeneEntrez gene idApproved name*FRMD6*122786FERM domain containing 6*LATS1*9113large tumor suppressor kinase 1*LATS2*26524large tumor suppressor kinase 2*MAP4K1*11184mitogen-activated protein kinase kinase kinase kinase 1*MAP4K2*5871mitogen-activated protein kinase kinase kinase kinase 2*MAP4K3*8491mitogen-activated protein kinase kinase kinase kinase 3*MAP4K4*9448mitogen-activated protein kinase kinase kinase kinase 4*MAP4K5*11183mitogen-activated protein kinase kinase kinase kinase 5*MINK1*50488misshapen like kinase 1*MOB1A*55233MOB kinase activator 1A*MOB1B*92597MOB kinase activator 1B*NF2*4771neurofibromin 2*PTPN14*5784protein tyrosine phosphatase, non-receptor type 14*RASSF1*11186Ras association domain family member 1*RASSF6*166824Ras association domain family member 6*SAV1*60485salvador family WW domain containing protein 1*STK3*6788serine/threonine kinase 3*STK38*11329serine/threonine kinase 38*STK38L*23012serine/threonine kinase 38 like*STK4*6789serine/threonine kinase 4*TAOK1*57551TAO kinase 1*TAOK2*9344TAO kinase 2*TAOK3*51347TAO kinase 3*TEAD1*7003TEA domain transcription factor 1*TEAD2*8463TEA domain transcription factor 2*TEAD3*7005TEA domain transcription factor 3*TEAD4*7004TEA domain transcription factor 4*TNIK*23043TRAF2 and NCK interacting kinase*VGLL4*9686vestigial like family member 4*WWC1*23286WW and C2 domain containing 1*WWTR1*25937WW domain containing transcription regulator 1*YAP1*10413Yes associated protein 1

Survival and correlation analyses {#Sec10}
---------------------------------

For each dataset, clinical-pathological features mainly affecting patients' survival according to the eighth edition of the American Joint Committee on Cancer^[@CR16]^ were taken into account as covariates. In order to directly compare the effect of genes and covariates, patients with missing values for any of the selected clinical-pathological parameters were removed from the analyses. For each gene, patients were divided into two groups, high and low expression levels, based on the median value. Also for age, the median was used to dichotomize patients. Survival curves were estimated with the Kaplan-Meier method and compared using the log-rank test. Multivariate Cox proportional hazard modelling of genes and covariates identified as potential prognostic factors in the univariate analyses was then used to determine their independent impact on patients' survival, and to estimate the corresponding hazard ratio, setting high expression as reference group. All survival analyses were performed with the survival R package version 2.41-3. All p values below 0.05 were considered to be statistically significant.

All genes identified as independent prognostic factors were correlated with YAP1 and YAP1pS127 protein expression levels using Pearson's correlation, following the procedures of Hmisc R package version 4.1-1. The flow chart of data analyses is reported in Fig. [4](#Fig4){ref-type="fig"}.Figure 4Flow chart of data analyses. Bold arrows and grey rectangles highlight the main path that led to obtained results and conclusions.

Review of literature {#Sec11}
--------------------

PubMed database ([www.ncbi.nlm.nih.gov/pubmed](http://www.ncbi.nlm.nih.gov/pubmed)) was used to search papers investigating Hippo genes and survival of cancer patients. All aliases provided by HUGO nomenclature ([www.genenames.org](http://www.genenames.org)) were used. Only English-written original articles were selected, and only papers containing original data and concerning protein or mRNA levels were considered.
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The datasets analysed during the current study are available at [www.cbioportal.org](http://www.cbioportal.org).
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